Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 266-257-8 | CAS number: 66215-27-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- 1985/09/03 to 1992/05/18
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
- Report date:
- 1992
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- EU Method B.9 (Repeated Dose (28 Days) Toxicity (Dermal))
- Deviations:
- yes
- Remarks:
- See below
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-2 (Repeated Dose Dermal Toxicity -21/28 Days)
- Principles of method if other than guideline:
- - The test substance was applied 5 days per week for 3 weeks instead of 7 days per week for 4 weeks.
- The spleen, testes, adrenals and heart were examined histopathologically only if macroscopic abnormalities had been detected post mortem. - GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- N-cyclopropyl-1,3,5-triazine-2,4,6-triamine
- EC Number:
- 266-257-8
- EC Name:
- N-cyclopropyl-1,3,5-triazine-2,4,6-triamine
- Cas Number:
- 66215-27-8
- Molecular formula:
- C6H10N6
- IUPAC Name:
- N2-cyclopropyl-1,3,5-triazine-2,4,6-triamine
Constituent 1
- Specific details on test material used for the study:
- Storage: room temperature
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Age at study initiation: Young adults
- Source: Ray Nichols Rabbitry, Lumberton, Texas
- Weight at study initiation: Males (2.100 - 3.025 kg), Females (2.200 - 3.025 kg)
- Housing: One per cage
- Food: Purina Rabbit Chow; available ad libitum
- Water Type: Tap water; available ad Iibitum
- Acclimation period: 30 days
ENVIRONMENTAL CONDITIONS
- Temperature: 20.6 - 23.3 °C
- Humidity: 57 - 79 %
- Air changes: 13 changes per hour
- Photoperiod: 12 hours light, 12 hours dark; 6:30-6:30 PM
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- water
- Remarks:
- Deionised water
- Details on exposure:
- The animals were prepared prior to the initial treatment by clipping the back of the trunk of each animal free of hair to expose approximately 10% of the total body surface area. Clipping was repeated on Days 3, 7, 10, 14, and 17 within twenty-four hours prior to dosing to ensure intimate contact of the test material with the skin and to facilitate the scoring of dermal reactions.
Animals were treated five times weekly for three weeks. Treatment days were Days 1, 2, 3, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 20, and 21. The three additional animals were treated on Days 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 20, 21, 22, 23, and 24. On each treatment day, the back of each animal was moistened with 3.0 ml of deionized water. The appropriate amount of test material was applied evenly over the back of each animal in the test item groups. A 4 x 8 inch surgical gauze patch (two layers thick) was then placed over the exposure area of each animal and was secured in place with a strip of non-irritating adhesive tape. The entire trunk of each animal was then loosely wrapped with a semi-permeable dressing (orthopedic stockinette). To secure the wrappings in place, the edges of the dressing were wrapped with non-irritating adhesive tape. Six hours after each treatment, the wrapping gauze, and tape were removed from each animal and the skin was gently washed with room temperature tap water to remove remaining test material. The animals were dried with a clean cloth and returned to their cages. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Stability/Homogeneity were both confirmed.
- Duration of treatment / exposure:
- 3 weeks
- Frequency of treatment:
- 6 hours per day, 5 days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 mg/kg bw/day
- Dose / conc.:
- 500 mg/kg bw/day
- Dose / conc.:
- 2 000 mg/kg bw/day
- No. of animals per sex per dose:
- 5/sex/group
One additional male was added to the 50 mg/kg bw group and two males were added to the 500 mg/kg bw group due to early non-treatment related deaths. - Control animals:
- yes
- Details on study design:
- The animals were assessed daily for any signs of systemic toxicity. Bodyweights and food consumption were recorded at intervals throughout the study. Twenty-four hours after the final application the animals were killed and blood samples taken for haematological and biochemical analysis. Each animal was subjected to a macroscopic examination post mortem, selected organs weighed and selected tissues examined microscopically.
- Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- Observations for skin irritation were made immediately prior to each application of Cyromazine. Observations for were made twice daily and observations for pharmacologic and/or toxicologic signs were made at least once daily. Individual body weights and food consumption were determined prior to the initial dosing, weekly throughout the study, and at termination of the study or at the time of discovery after death. Twenty-four hours after the final application the animals were killed and blood samples taken for haematological and biochemical analysis.
- Sacrifice and pathology:
- Twenty-four hours after the final application the animals were killed and blood samples taken for haematological and biochemical analysis. Each animal was subjected to a macroscopic examination post mortem, selected organs weighed and selected tissues examined microscopically.
- Statistics:
- All statistics and calculations were performed by computer with appropriate statistical
software.
Hematology values (except for differential leukocyte counts), all clinical chemistry values, and
Day 21 body weights were analyzed by Analysis of Variance (ANOVA). Statistical differences
found by ANOVA were further analyzed by Dunnett’s test and/or Student’s t-test. If any parameter
for a treatment group was found significantly different from the control for the terminal values, then the corresponding baseline values were also analyzed by the Analysis of Variance. Organ to body weight ratios and differential leukocyte counts were analyzed by the Kruskal-Wallis test. Ryan’s procedure for the Mann-Whitney U test was used to elicit differences indicated by the Kruskal-Wallis test. All statistical analysis were tested for significance at 0.05 and 0.01 alpha levels. If p > 0.05, the difference was judged non-significant.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Clinical observations were generally minor. Changes in bowel and bladder function were observed in all groups and occurred more frequently during the first part of the study; these changes could have been in response to wrapping and handling of the animals. Other clinical observations included very slight to moderate diarrhea, decreased activity, emaciation, lacrimation, yellow nasal discharge and ataxia, however, these effects were not dose-related and were considered not to be related to treatment.
- Dermal irritation:
- no effects observed
- Description (incidence and severity):
- The 21-day dermal exposure to cyromazine produced no observable skin irritation.
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- Six animals died during the study but without dose-response correlation to treatment i.e. there were no deaths at the highest dose, while deaths occurred in control (one male), at 50 mg/kg (one female) and at 500 mg/kg (two males and two females). Mortality was thus concluded not to be related to exposure to the test item.
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no dose related effects on body weight or food consumption.
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no dose-related differences in the clinical chemistry or haematological parameters measured in treated animals compared to control.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Serum creatinines increased over the duration of the study in all four groups, both male and female. There was a decline of serum chloride and potassium values between baseline and terminal determinations in all groups. A significant increase in serum glucose between baseline and terminal measurements was observed in exposed males. However, in these cases mean values were within normal ranges, and there were no statistically significant differences among the groups.
- Urinalysis findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no dose-related differences in organ weights, organ/body weight ratios, organ/brain weight ratios or histopathology in treated animals compared to control.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- No test material-related effects were observed in any of the animals.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- A number of histopathologic changes indicative of low grade infection or parasite migration were observed in liver, kidneys and lungs taken at sacrifice from all four groups. These findings were considered not to be related to treatment.
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 2 000 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other:
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
Table 1:
21 Day Dermal Study in Rabbits (mortality data)
Dose level | Time of death | Number of deaths | |
(mg/kg b.w.) | (Day) | Male | Female |
0 | 20 | 1/5 | 0/5 |
| Total at day 21 | 1/5 | 0/5 |
50 | 21 | 0/6 | 1/5 |
| Total at day 21 | 0/6 | 1/5 |
500 | 4 | 1/7 | 0/5 |
| 7 | 1/7 | 1/5 |
| 11 | 0/7 | 1/5 |
| Total at day 21 | 2/7 | 2/5 |
2000 | Total at day 14 | 0/5 | 0/5 |
See "Overall remarkes, attachement" for the rest of tables
Applicant's summary and conclusion
- Conclusions:
- Based on the results of a dermal 28-day repeated dose toxicity study, the NOAEL was considered to be 2000 mg/kg bw/day.
- Executive summary:
A 21-day dermal toxicity study was conducted on male and female albeno rabbits using Cyromazine. Twenty-three male and twenty female albino rabbits were selected for testing. Five males and five females were randomly selected for each of the four treatments groups. One additional male was added to the low dose group and two males were added to the mid dose group because of early non-treatment related deaths. The exposure areas of all animals were moistened with 3.0 ml of deionized water. The animals in the test item groups were treated with 50, 500, 2000 mg/kg bw of the test material, respectively. The Vehicle Control animals were treated only with 3.0 ml of deionized water. The exposure period lasted for 6 hours per day. The treatment regimen was repeated five times weekly for 3 weeks.
Several deaths occurred with no dose-response correlation to treatment, i.e., there were no deaths at the highest dose, while deaths did occur in Control (one male), low dose (one female), and high dose group (two males and two females). The mortality was concluded not to be related to the test item exposure. No dose-related effects on in-life observations, mortality, body weights, food consumption, skin reactions, hematology, clinical chemistry, organ weights, organ/body weight ratios, organ/brain weight ratios, or histopathology were produced by the repeated dermal administration of Cyromazine at up to 2000 mg/kg bw/day, two times the limit dose. Based on the absence of adverse effects, the NOAEL was concluded to be 2000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.